Atypical Hemolytic Uremic Syndrome (aHUS)

Also known as: Atypical Hemolytic Uraemic Syndrome / Atypical Hemolytic-Uremic Syndrome / Atypical Hemolytic Uremic Syndrome / Hemolytic-Uremic Syndrome, Atypical / Hemolytic Uremic Syndrome, Atypical / Atypical hemolytic uremic syndrome (disorder) / Atypical haemolytic uraemic syndrome / AHUS

DrugDrug NameDrug Description
DB01257EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
DB11580RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
DrugDrug NamePhaseStatusCount
DB15011Avacopan2Terminated1
DB16121Cemdisiran2Withdrawn2
DB01257Eculizumab2Completed8
DB16128Crovalimab3Recruiting2
DB16200Iptacopan3Recruiting1
DB16418Narsoplimab3Unknown Status1
DB11580Ravulizumab3Active Not Recruiting2
DB01257Eculizumab4Completed1
DB01257Eculizumab4Recruiting1
DB01257EculizumabNot AvailableCompleted1